Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Sign Up for CMTA eNews
Thank you for your interest in signing up for CMTA E-News. We look forward to keeping you informed about CMTA research, events, fundraising and more! By submitting this form, you…
Innervator Hall of Fame
…of impact, it’s great to see such a large part of our donations go towards research and education. Far too many organizations spend a significant amount of donations on administration…
The 2021 CMTA Annual Report
…our community outreach efforts invigorate and inform our research efforts, with the community providing the energy, excitement and funding for the research. You’ll read about all of it in the…
CMTA and Addex Announce CMT1A Collaboration
…of key outcomes. These outcome measures include biomarkers, motor function, electrophysiology and peripheral nerve histology. This is made possible through the CMTA’s preclinical testing alliance: www.cmtausa.org/our-research/for-researchers/cmta-preclinical-testing-network/ Download the full release…
Medications and Charcot-Marie-Tooth Disease
There currently are no available treatments that act to slow the progression of Charcot-Marie-Tooth disease. There are promising CMT research studies that indicate that this may change in the near…
Evolution: CMTA Board Welcomes Coulie & Marks
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of Bernard…
Links to CMTA Resources
Learn more CMTA Webinars: www.cmtausa.org/webinars STAR Research: www.cmtausa.org/our-research Dr. Scherer on Pain: www.cmtausa.org/painpdf Ask the Experts: www.cmtausa.org/cmtexperts Neurotoxic Drug List: www.cmtausa.org/medicationlist Connect with us CMTA Facebook Page: www.facebook.com/CMTAssociation…
CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients
…their families. The CMTA has invested $23.5 million in the search for a cure and its Strategy to Accelerate Research (STAR) brings world-renowned CMT researchers together with pharmaceutical and biotechnology…
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
…and Chief Executive Officer of Acceleron. “We wish to thank all of the patients, families, caregivers, and investigators for their support and participation in this research. I also want to…
CMTA Lunch & Learn: End of the Year Fireside Chat and Q/A
12/20/2023 @ 12:00 pm – 1:00 pm – Please join us (via ZOOM) for our last “Lunch & Learn” Webinar of the year on Wednesday, December 20th at 12:00 p.m. Eastern Time for one hour where we will welcome special guests Sue Bruhn, PhD, the CMTA’s CEO, and Katherine Forsey, PhD, the CMTA’s Chief Research Officer. The purpose of this meeting is two-fold: […]